RA patients place higher value on treatment benefits over attributes for DMARD therapy
Patients with rheumatoid arthritis (RA) who are being treated with disease-modifying antirheumatic drug (DMARD) therapy value treatment benefits more than treatment attributes, such as serious or minor side effects, cost, or route of administration, a study has shown.